Incyte signed an asset purchase agreement with MorphoSys, which gives Incyte exclusive global rights for tafasitamab, marketed as Monjuvi in the U.S.
“This new agreement with MorphoSys provides Incyte with exclusive global rights to tafasitamab and full control over its development and commercialization, allowing us to realize significant operating efficiencies and cost synergies,” said Hervé Hoppenot, Incyte CEO.
Under the previous agreement, MorphoSys and Incyte were collaborating and sharing costs for the clinical development and commercialization of tafasitamab in the U.S.; Incyte had exclusive rights outside of the U.S. Under the terms of the new agreement, MorphoSys will receive a payment of $25 million from Incyte, and Incyte will gain global development and commercialization rights for tafasitamab. Incyte will now recognize revenue and cost for all U.S. commercialization and clinical development, and MorphoSys will no longer be eligible to receive future milestone, profit split, and royalty payments.
Annual sales of the drug as of 2023 were $92 million.
In the United States, Monjuvi is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory Diffuse large B cell lymphoma (DLBCL), the most common lymphoma, accounting for about 25% to 30% of all non-Hodgkin lymphoma. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Incyte is based near Wilmington and has 1,500 employees in Delaware and in adjacent areas of Pennsylvania. MorphoSys is based in Germany.
Incyte’s blockbuster drug in Jakfafi, a drug used to treat blood cancers and related conditions.
